Posez n’importe quelle question sur les cours, conférences, exercices, recherches, actualités, etc. de l’EPFL ou essayez les exemples de questions ci-dessous.
AVERTISSEMENT : Le chatbot Graph n'est pas programmé pour fournir des réponses explicites ou catégoriques à vos questions. Il transforme plutôt vos questions en demandes API qui sont distribuées aux différents services informatiques officiellement administrés par l'EPFL. Son but est uniquement de collecter et de recommander des références pertinentes à des contenus que vous pouvez explorer pour vous aider à répondre à vos questions.
Methods and compositions are provided for treating a host having a gastrointestinal (GI) disease by administering to the host a composition containing a pharmaceutically effective amount of a modulator of a Peroxisome Proliferator Activated Receptor (PPAR) ...
PPARgamma is a member of the peroxisome proliferator activated receptors (PPAR) subfamily of nuclear receptors. So far two PPARgamma isoforms, PPARgamma1 and PPARgamma2, were known in mammals. We describe the structure of a novel human PPARgamma subtype, P ...
The three types of peroxisome proliferator-activated receptors (PPAR), termed alpha, delta (or beta), and gamma, belong to the nuclear receptor superfamily. Although peroxisome proliferators, including fibrates and fatty acids, activate the transcriptional ...
The peroxisome proliferator activated receptors or PPARs constitute a subfamily of the nuclear hormone receptor superfamily of transcription factors. PPARs form heterodimeric complexes with the 9-cis retinoic acid receptor (RXR), which bind to specific res ...
Members of the nuclear receptor family are involved in an increasing number of processes in the cell. These receptors can directly regulate gene expression by binding to DNA. The molecular basis for transcriptional activation is so far not well understood. ...
The regulation of liver apolipoprotein (apo) A-I gene expression by fibrates was studied in human apo A-I transgenic mice containing a human genomic DNA fragment driving apo A-I expression in liver. Treatment with fenofibrate (0.5% wt/wt) for 7 d increased ...
This invention relates to methods and compositions for the prevention and treatment of Type 2 diabetes and cardiovascular disease with diabetic or pre-diabetic conditions or symptoms associated therewith using both a PPAR gamma agonist and a PPAR alpha ago ...
Increased activity of lipoprotein lipase (LPL) may explain the hypotriglyceridemic effects of fibrates, thiazolidinediones and fatty acids, which are known activators (and/or ligands) of the various peroxisome proliferator-activated receptors (PPARs). Trea ...
The development of atherosclerosis is often associated with altered concentrations of systemic lipoproteins, which are determined by the concentration and/or activity of three groups of different proteins, i.e. apolipoproteins (apo), enzymes, and receptors ...
The long-chain acyl-coenzyme A synthetase (ACS) gene gives rise to three transcripts containing different first exons preceded by specific regulatory regions A, B, and C. Exon-specific oligonucleotide hybridization indicated that only A-ACS mRNA is express ...
